FDA Approves Olaparib for Patients with Metastatic Breast Cancer and BRCA Mutation

The FDA has expanded the approval of olaparib (Lynparza) for patients with metastatic breast cancer who have a germline BRCA genetic mutation. Olaparib, a PARP...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news